-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Cisplatin chemotherapy is recommended for patients with muscular-invasive bladder cancer (MIBC), followed by radical cystectomy (RC
Recently, researchers from the Netherlands published an article in World J Ulol comparing the clinical outcomes of preoperative gem-carbo and gem-carbo after 3 cycles of ≥ treatment
The study included 1865 patients
A total of 747 patients treated with gem-carbo (n=147) and gem-cis (n=600) were included in the
Comparison of overall survival between the two treatment groups
In summary, some MIBC patients who do not meet the conditions for cisplatin use obtain pCR in gem-carbo treatment, and if the patient can undergo ≥ 3 cycles and receive RC treatment, their survival outcomes may be comparable
Original Source:
Sarah M H Einerhand , Anna J Black , Homayoun Zargar et al.